News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

UCB, Inc. (UCBJF.PK) Launches Neupro® in the U.S. to Treat Parkinson's Disease and Restless Legs Syndrome


7/16/2012 9:43:15 AM

BRUSSELS & ATLANTA--(BUSINESS WIRE)--UCB announced today that Neupro® (Rotigotine Transdermal System) is now available in U.S. pharmacies. Neupro® was approved by the U.S. Food and Drug Administration in April to treat the signs and symptoms of early and advanced stage idiopathic Parkinson’s disease and moderate-to-severe primary Restless Legs Syndrome.

Read at BioSpace.com

Related News

comments powered by Disqus
UCB, Inc.
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES